Company: SUPN
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001356576-25-000055
Chunk: 80

Company: SUPERNUS PHARMACEUTICALS, INC.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 80
---
(27,295)— (27,295)Reclassification to Other Current Liabilities(27,705)(27,705)Balance at June 30, 2025 (unaudited)$— $— $— USWM AcquisitionAdamas AcquisitionTotalBalance at December 31, 2023$46,400 $7,050 $53,450 Change in fair value recognized in earnings(1,170)(4,280)(5,450)Balance at June 30, 2024 (unaudited)$45,230 $2,770 $48,000 The Company recorded the following changes in fair value of the contingent consideration liability for the USWM milestones:•The Company recorded  a $7.7 million expense due to the change in fair value of contingent consideration liabilities for the USWM milestones for the six months ended June 30, 2025. No expense was recorded during the three months ended June 30, 2025. The Company recorded a $1.9 million gain and a $1.2 million gain due to the change in the fair value of the contingent consideration liabilities for the USWM milestones for the three and six months ended June 30, 2024, respectively. The change in fair value of contingent consideration was primarily due to accretion to the full milestone payment amount with the achievement of the milestones. ONAPGO was approved by the FDA in February 2025 and was launched in April 2025. The Company recorded the following changes in fair value of the contingent consideration liabilities for the Adamas CVRs:

•The Company recorded a $2.5 million gain and a $4.3 million gain due to the change in fair value of the contingent consideration liabilities for the Adamas CVRs for the three and six months ended June 30, 2024. The change in fair value of contingent consideration was primarily due to passage of time. 

14

7.    Intangible Assets, Net

The following table sets forth the gross carrying amounts and related accumulated amortization of intangible assets (dollars in thousands):June 30, 2025December 31, 2024(unaudited)Remaining WeightedAverage Life (Years)Carrying Amount, GrossAccumulated AmortizationCarrying Amount, NetCarrying Amount, GrossAccumulated AmortizationCarrying Amount, NetAcquired in-process research and development$— $— $—